Viridian Therapeutics's total assets for Q2 2025 were $582.32M, a decrease of -11.90% from the previous quarter. VRDN total liabilities were $67.16M for the fiscal quarter, a 18.84% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.